Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 119pembrolizumab 105Specimen Handling 105Magnetic Resonance Spectroscopy 95fludarabine 93Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 37Carboplatin 36Paclitaxel 35Cetuximab 34Radiotherapy 31fludarabine phosphate 30Oxaliplatin 30Leucovorin 28Gemcitabine 27Drug Therapy 25Immunotherapy, Adoptive 23Azacitidine 23Ipilimumab 22Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × MAC-ST-001 × Clear all
NCT06922539 2025-12-15

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

SciTech Development, Inc.

Phase 1 Recruiting
44 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡